BiogenedWAR:BGD 68 EBITDA Margin % is 19.72% as of Mar. 2026, which is 35% above its 10-year median of 14.60. GuruFocus rates WAR:BGD with a GF Score™ of 68/100 and a GF Value™ of zł23.80 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 954 Drug Manufacturers companies, Biogened ranks better than 50.73% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biogened's EBITDA for the
three
months ended in Mar. 2026 was zł5.6 Mil. Biogened's Revenue for the
three
months ended in Mar. 2026 was zł28.3 Mil. Therefore, Biogened's EBITDA margin for the quarter that ended in Mar. 2026 was 19.72%.
Biogened (WAR:BGD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biogened EBITDA Margin % Related Terms
Biogened EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Biogened's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:BGD vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogened EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogened's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biogened's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogened (WAR:BGD) has a EBITDA Margin % of 19.72% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biogened and its competitors. This is 35% above median its historical median of 14.60. Over the past decade, Biogened's EBITDA Margin % has ranged from 10.86 to 21.79. According to the industry distribution chart, Biogened ranks #470 out of 954 companies in the Drug Manufacturers industry, placing it in the top 49.3%.
Is Biogened's EBITDA Margin % too high?
Biogened's current EBITDA Margin % of 19.72% is 35% above median its 10-year median of 14.60. Over the past 10 years, this metric has ranged from a low of 10.86 to a high of 21.79. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Biogened's value of 19.72% is 57.6% above this industry median. Based on the distribution chart, Biogened ranks #470 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogened has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biogened ranks #470 out of 954 companies for EBITDA Margin %. This puts Biogened in the upper half of its industry. The industry median EBITDA Margin % is 12.52. Biogened's value of 19.72% is 57.6% above this benchmark. Historically, Biogened's own EBITDA Margin % has ranged from 10.86 to 21.79 over the past decade. While the company's 10-year median is 14.60 vs. the industry median of 12.52, Biogened has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogened's current EBITDA Margin % of 19.72% is 57.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biogened and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogened's current EBITDA Margin % is 19.72%, which is 35% above median its own 10-year median of 14.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.80, compared to a current price of zł18.40 — trading 22.7% below its estimated fair value. The current EBITDA Margin % is 19.72%, which is 35% above median its 10-year median of 14.60 and 57.6% above the Drug Manufacturers industry median of 12.52. Biogened's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biogened (WAR:BGD), the current EBITDA Margin % is 19.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogened (WAR:BGD) Overvalued in 2026?
Based on GuruFocus' analysis, Biogened stock appears to be undervalued.
The current stock price of zł18.40 is trading 22.7% below its estimated GF Value™ of zł23.80.
GuruFocus considers Biogened to be Modestly Undervalued.
Key valuation signals for WAR:BGD:
EBITDA Margin %: 19.72% (35% above median its 10-year median of 14.60)
GF Value™: zł23.80 vs. price of zł18.40 (22.7% below fair value)
Industry Position: 57.6% above the Drug Manufacturers median (#470 of 954)
No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
68GF Score
Get the complete analysis for WAR:BGD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BGD has been successfully added to your 
